MTOR inhibition: The learning curve in kidney transplantation

Transplant International

Volumn 23, Issue 5, 2010, Pages 447-460

  Weir, Matthew R ^a   Diekmann, Fritz ^b   Flechner, Stuart M ^c   Lebranchu, Yvon ^d   Mandelbrot, Didier A ^e   Oberbauer, Rainer ^f   Kahan, Barry D ^g  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^d UNIVERSITÉ DE TOURS   (France)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Graft survival; Kidney; MTOR inhibition; Rejection; Transplantation

Indexed keywords

ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CHOLESTEROL; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 3A4; DACLIZUMAB; EVEROLIMUS; FINGOLIMOD; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; IOTALAMIC ACID; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN; RAPAMYCIN; STEROID; TACROLIMUS; TEMSIROLIMUS; TRIACYLGLYCEROL; MTOR PROTEIN, HUMAN; MTOR PROTEIN, MOUSE; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ACNE; ACUTE GRAFT REJECTION; APHTHOUS STOMATITIS; APOPTOSIS; AREA UNDER THE CURVE; BLOOD DISEASE; BODY MASS; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER SURVIVAL; CELL ACTIVATION; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; FOLLICULITIS; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; HYPOKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTERSTITIAL PNEUMONIA; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; KIDNEY INJURY; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LUNG DISEASE; LYMPHATIC SYSTEM INFECTION; MAJOR CLINICAL STUDY; MALE FERTILITY; MOUTH ULCER; NONHUMAN; PERIPHERAL EDEMA; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RESTENOSIS; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SKIN CANCER; STREPTOMYCES HYGROSCOPICUS; TRANSPLANTATION; WOUND HEALING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; COMPLICATION; KIDNEY NEOPLASMS; METABOLISM; MOUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; KIDNEY TRANSPLANTATION; MICE; MODELS, BIOLOGICAL; PROTEIN-SERINE-THREONINE KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOR SERINE-THREONINE KINASES;

EID: 77950639660     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01051.x     Document Type: Review

References (112)

1. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001 72 : 1181.
2. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006 81 : 1234.
3. Bennett WM. Insights into chronic cyclosporine nephrotoxicity. Int J Clin Pharmacol Ther 1996 34 : 515.
4. Myers BD, Newton L. Cyclosporine-induced chronic nephropathy: an obliterative microvascular renal injury. J Am Soc Nephrol 1991 2 (Suppl. 1 S45.
5. Pascual M, Swinford RD, Ingelfinger JR, Williams WW, Cosimi AB, Tolkoff-Rubin N. Chronic rejection and chronic cyclosporin toxicity in renal allografts. Immunol Today 1998 19 : 514.
6. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998 66 : 1736.
7. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006 6 : 514.
8. Grinyó JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant 2006 6 : 1991.
9. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004 4 : 1776. (Pubitemid 39434437)
10. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007 357 : 2562. (Pubitemid 350294223)
11. Sturgill TW, Hall MN. Holding back TOR advances mitosis. Nat Cell Biol 2007 9 : 1221.
12. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006 124 : 471. (Pubitemid 43199434)
13. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004 18 : 446. (Pubitemid 39077081)
14. Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005 80 : 749. (Pubitemid 41443756)
15. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000 11 : 1735.
16. Vajdic CM, McDonald SP, McCredie MRE, et al. Cancer incidence before and after kidney transplantation. JAMA 2006 296 : 2823.
17. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007 83 : 883. (Pubitemid 46682728)
18. Kahan BD, Chang JY, Sehgal SN. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 1991 52 : 185.
19. Sehgal SN, Baker H, Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975 28 : 727.
20. Rapamune [Package Insert].
21. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991 253 : 905.
22. Cypher Sirolimus-Eluting Coronary Stent [Instructions for Use].
23. Torisel Kit (Temsirolimus) [Package Insert].
24. ® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998 31 : 335.
25. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: part I. Circulation 2003 107 : 2274.
26. Ikonen TS, Gummert JF, Hayase M, et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 2000 70 : 969.
27. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005 11 : 353.
28. Koehl GE, Andrassy J, Guba M, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004 77 : 1319. (Pubitemid 38668421)
29. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005 352 : 1317. (Pubitemid 40411498)
30. Chapman JR, Valantine H, Albanell J, et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 2007 39 : 2937. (Pubitemid 350258649)
31. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007 7 : 1722. (Pubitemid 46905432)
32. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001 40 : 573. (Pubitemid 32758580)
33. Zimmerman JJ, Ferron GM, Lim HK, Parker V. The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol 1999 39 : 1155. (Pubitemid 30644018)
34. Yatscoff RW, Wang P, Chan K, Hicks D, Zimmerman J. Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 1995 17 : 666.
35. Kelly PA, Gruber SA, Behbod F, Kahan BD. Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy 1997 17 : 1148. (Pubitemid 27518028)
36. Mathew TH, Van Buren C, Kahan BD, Butt K, Hariharan S, Zimmerman JJ. A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection. J Clin Pharmacol 2006 46 : 76. (Pubitemid 43021716)
37. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001 12 : 1059. (Pubitemid 32378348)
38. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004 43 : 83. (Pubitemid 38283132)
39. Certican [Package Insert].
40. Kirchner GI, Winkler M, Mueller L, et al. Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. Br J Clin Pharmacol 2000 50 : 449.
41. Kovarik JM, Beyer D, Schmouder RL. Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Dispos 2006 27 : 421. (Pubitemid 46062146)
42. Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996 49 : 209. (Pubitemid 26024236)
43. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche H-U, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998 66 : 1040. (Pubitemid 28513384)
44. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 1999 68 : 1526.
45. Groth CG, Bäckman L, Morales J-M, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999 67 : 1036. (Pubitemid 29200856)
46. Kreis H, Cisterne J-M, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000 69 : 1252. (Pubitemid 30238708)
47. Kahan BD. Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc 2003 35 (Suppl. 3A 37S.
48. Johnson RWG, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001 72 : 777. (Pubitemid 32879845)
49. Gaber AO, Kahan BD, Van Buren CT, et al. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. Transplantation 2008 86 : 1187.
50. Flechner S, Glyda MJ, Steinberg S, Harler MB, for the ORION Trial Investigators. A randomized, open-label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (Tac) and mycophenolate mofetil (MMF) regimen in de novo renal allograft recipients: renal function results from the ORION study (abstract). Am J Transplant Poster Presented at: American Transplant Congress; May 5-9, 2007; San Francisco, CA 2007 7 (Suppl. 2 440.
51. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009 87 : 233.
52. Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006 82 : 1153.
53. Patel A, Weir M, Wali R, Pearson T, Mulgaonkar S, Shidban H. Spare-the-Nephron (STN) trial: updated analysis of renal function after one year of mycophenolate mofetil/sirolimus maintenance therapy and calcineurin inhibitor withdrawal in renal transplant recipients. Am J Transplant Poster Presented at: American Transplant Congress; May 5-9, 2007; San Francisco, CA 2007 7 (Suppl. 2 439.
54. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002 74 : 1070.
55. Hamdy AF, El-Agroudy AE, Bakr MA, et al. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Am J Transplant 2005 5 : 2531.
56. Hamdy AF, Bakr MA, Ghoneim MA. Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients. J Am Soc Nephrol 2008 19 : 1225.
57. ®, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007 7 : 2522.
58. Lo A, Egidi MF, Gaber LW, et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Transplantation 2004 77 : 1228.
59. Martinez-Mier G, Mendez-Lopez MT, Budar-Fernandez LF, et al. Living related kidney transplantation without calcineurin inhibitors: initial experience in a Mexican center. Transplantation 2006 82 : 1533.
60. Schaefer HM, Kizilisik AT, Feurer I, et al. Short-term results under three different immunosuppressive regimens at one center. Transplant Proc 2006 38 : 3466.
61. Figueiro JM, Vilaca SS, Gontijo RC, Souza GS. CNI-free immunosuppression in de novo kidney transplantation. Am J Transplant Poster Presented at: American Transplant Congress; May 5-9, 2007; San Francisco, CA 2007 7 (Suppl. 2 160.
62. Holm A, Hernandez M, Camarena A. Efficacy, tolerability, and safety of mycophenolate mofetil (CellCept) + sirolimus (Rapamune) as maintenance therapy after calcineurin inhibitor withdrawal in LRD and CAD adults and pediatric renal transplant recipients (experience with 405 patients). Transplantation 2008 86 (Suppl. 2 220.
63. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004 77 : 1555.
64. McTaggart RA, Tomlanovich S, Bostrom A, Roberts JP, Feng S. Comparison of outcomes after delayed graft function: sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens. Transplantation 2004 78 : 475.
65. Smith KD, Wrenshall LE, Nicosia RF, et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003 14 : 1037.
66. Lebranchu Y, Toupance O, Touchard G, et al. Impact on Renal Function of Early Conversion at 3 Months from Cyclosporine (CsA) to Sirolimus (SRL) in Association with Mycophenolate Mofetil (MMF) in Kidney Transplantation: 30-Months Follow Up of a Multicenter Randomized Controlled Trial: The Concept Study.
67. Flechner S, Glyda M, See Tai S, et al. Delayed Graft Function (DGF) in Two Sirolimus (SRL)-Based Regimens Compared with Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) in De Novo Renal Allograft Recipients.
68. Vítko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004 78 : 1532.
69. Lorber MI, Mulgaonkar S, Butt KMH, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005 80 : 244.
70. Lorber MI, Ponticelli C, Whelchel J, et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant 2005 19 : 145.
71. Tedesco-Silva H Jr., Vitko S, Pascual J, et al., 2306 and 2307 study groups. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 2007 20 : 27.
72. Chan L, Greenstein S, Hardy MA, et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008 85 : 821.
73. Kovarik JM, Tedesco-Silva H, Lorber MI, Foster C. Exposure-efficacy relationships of a fingolimod-everolimus regimen in kidney transplant patients at risk for delayed graft function. Transplant Proc 2006 38 : 3479.
74. Montagnino G, Sandrini S, Iorio B, et al. A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. Nephrol Dial Transplant 2008 23 : 707.
75. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009 9 : 1115.
76. Pearson TC, Mulgaonkar S, Patel A, et al. Efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal in renal transplant recipients: final results of the Spare-the-Nephron (STN) trial. Am J Transplant 2008 8 (Suppl. 2 213.
77. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004 4 : 1869.
78. Wali RK, Mohanlal V, Ramos E, et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007 7 : 1572.
79. McDonald S, Excell L, Livingston B. Deaths., eds. ANZDATA Registry: The Thirtieth Report.
80. Papaconstantinou HT, Sklow B, Hanaway MJ, et al. Characteristics and survival patterns of solid organ transplant patients developing de novo colon and rectal cancer. Dis Colon Rectum 2004 47 : 1898.
81. US Renal Data System. Transplantation. 2003 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.
82. US Renal Data System. Transplantation. 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States.
83. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999 397 : 530.
84. Wimmer CD, Rentsch M, Crispin A, et al. The janus face of immunosuppression -de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int 2007 71 : 1271.
85. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002 73 : 1565.
86. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005 80 : 883.
87. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002 8 : 128.
88. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006 17 : 581.
89. Vítko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005 5 : 2521.
90. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 2004 78 : 1332.
91. Ekberg H, Grinyó J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007 7 : 560.
92. Servais A, Meas-Yedid V, Lebranchu Y, et al. Comparison at one year of interstitial fibrosis (IF) by automatic quantification in renal transplant recipients with cyclosporine (CsA) discontinuation and sirolimus (SRL) introduction. Am J Transplant Abstract presented at: American Transplant Congress; May 30-June 4, 2008; Toronto, Ontario, Canada 2008 8 (Suppl. 2 319.
93. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007 356 : 2271.
94. Kahan BD, for The Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000 356 : 194.
95. Morelon E, Stern M, Israel-Biet D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001 72 : 787.
96. Chueh S-C, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003 76 : 375.
97. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008 19 : 1411.
98. Roland M, Gatault P, Doute C, et al. Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation. Transpl Int 2008 21 : 523.
99. Zuber J, Anglicheau D, Elie C, et al. Sirolimus may reduce fertility in male renal transplant recipients. Am J Transplant 2008 8 : 1471.
100. Flechner SM, Zhou L, Derweesh I, et al. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients. Transplantation 2003 76 : 1729.
101. Kamar N, Jaafar A, Esposito L, et al. Conversion from sirolimus to everolimus in maintenance renal transplant recipients within a calcineurin inhibitor-free regimen: results of a 6-month pilot study. Clin Nephrol 2008 70 : 118.
102. Tenderich G, Fuchs U, Zittermann A, Muckelbauer R, Berthold HK, Koerfer R. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant 2007 21 : 536.
103. Abramowicz D, Hadaya K, Hazzan M, et al. Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects. Nephrol Dial Transplant 2008 23 : 3727.
104. Flechner SM, Feng J, Mastroianni B, et al. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation 2005 79 : 926.
105. Büchler M, Lebranchu Y, Bénéton M, et al. Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. Clin Pharmacol Ther 2005 78 : 34.
106. Cattaneo D, Merlini S, Zenoni S, et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant 2005 5 : 2937.
107. Figurski MJ, Nawrocki A, Pescovitz MD, Bouw R, Shaw LM. Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine. Ther Drug Monit 2008 30 : 445.
108. Le Meur Y, Djebli N, Szelag JC, et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 2006 80 : 51.
109. Kalil R, Pearson T, Mulgaonkar S, et al. Final 1-Year Outcomes of the Spare-the-Nephron (STN) Trial: Mycophenolate Mofetil (MMF)-Based Regimen Combined with Sirolimus (SRL) to Preserve Renal Function in Renal Transplantation.
110. Ruiz JC, Campistol JM, Sanchez-Fructuoso A, et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 2006 21 : 3252.
111. Letavernier E, Bruneval P, Mandet C, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007 2 : 326.
112. Letavernier E, Pe'raldi M-N, Pariente A, Morelon E, Legendre C. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005 80 : 1198.